SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs Q3 earnings report is the dominant focus, with traders debating whether a strong report and raised guidance can overcome elevated expectations amid a broader AI-stock pullback. Bulls point to continued AI growth, while bears warn that a beat may not be enough to prevent profit-taking or valuation pressure.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Attention centers on Zevras quarterly results and the pending CHMP re-examination of MIPLYFFA, with the FDAs follow-up on celiprolol also viewed as a potential catalyst. Traders see U.S. MIPLYFFA growth as a support, but debate whether European regulators will reverse their earlier negative opinion, while some express frustration with management and the stocks volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Anticipation for QUILT-2.005 topline results on ANKTIVA plus BCG in BCG-naive bladder cancer dominates discussion, with traders debating whether the data will support broader first-line use after ANKTIVAs expanded bladder-cancer approval. Many are bullish on the potential commercial expansion and upcoming earnings, while others cite execution and competition concerns and blame short selling for recent weakness.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL immunotherapy data presented at ESMO, including early neoadjuvant colon cancer responses and sarcoma activity, are driving discussion. Bulls view the findings as promising validation, while skeptics point to small, nonrandomized studies and ongoing concerns about execution and dilution.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results have focused attention on heavy AI infrastructure spending and its impact on cash flow, despite accelerating AWS growth that fell short of some investors expectations. Traders are split between worrying that the spending and financing burden may outweigh near-term returns and viewing the post-earnings selloff as an overreaction to strong cloud demand.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is caught in a semiconductor selloff as traders question whether hyperscalers massive AI spending will generate sufficient returns, with concerns about customer concentration and financing structures weighing on sentiment. Bulls counter that Anthropics filing and bank-backed financing for Broadcom equipment support future demand, while others see the deals guarantees as added risk.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

Traders are focused on SCO as a leveraged inverse-crude play, betting that oil could fall if Iran-related tensions ease and supply flows normalize, while others expect conflict and shipping disruptions to keep crude elevated. Many also complain that backwardation and daily-reset decay have caused SCO to lag oils declines, fueling debate over its tracking and suitability for longer holds.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is under pressure after its latest earnings despite beating expectations and raising its outlook, as traders focus on slower cloud net-new ARR growth and cautious second-half guidance. Bulls view the pullback as profit-taking after a strong run and point to continued business growth, while skeptics argue high expectations and the guidance outlook warrant a lower valuation.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

A stronger-than-expected Q3 report and raised full-year outlook are supporting bullish attention, alongside Mercks Moderna-partnered melanoma vaccine meeting Phase 3 endpoints with Keytruda. Traders see potential oncology-platform value, but debate whether the results meet high expectations and how much upside the vaccine may add for Merck.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPaths sharp selloff following its earnings and Investor Day, alongside analyst downgrades and price-target cuts, is driving discussion; skeptics say growth and AI monetization still need to show up in results, while bulls see the companys agentic-AI orchestration strategy and cash position as undervalued.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should Vanguard Morningstar Mid-Cap ETF (VO) Be on Your Investing Radar?

ALNY Stock Hits Fresh 52-Week Low On Medicare Access Worries And Pipeline Delays

Equity

Alnylam management said it now expects full-year TTR product sales to land at the low end of its $4.2 billion to $4.5 billion range.


RKLB Stock Slides 8% After Hours As Neutron Debut Slips Into 2027 Over Manufacturing Issues: CEO Says ‘Possible Success Isn’t Our Standard’

Rocket Lab CEO Peter Beck pinned the delay on manufacturing issues identified in the forward propellant dome on the launch vehicle’s first stage. 


MDB Stock Dives After-Hours Despite Raised Full-Year Forecast — What’s Driving The Selloff?

For the current quarter, MongoDB guided to $756 million to $761 million in revenue and $1.57 to $1.61 in adjusted earnings, a step down from the just-finished quarter. 


RDDT Stock Jumps 11% After-Hours — What's Driving The Rally?

Reddit Inc. will replace AvalonBay Communities Inc. (AVB) in the S&P 500 effective prior to the opening of trading on Tuesday, August 18.


RKLB Slips After Hours On Q2 Earnings Miss But Retail Traders Cheer Strong Order Backlog, Upcoming Neutron Launch

Combined with deals signed since Q2 closed, Rocket Lab has already booked more than $1 billion in new launch and space systems contracts, the firm said.


HPE Stock Jumps After Morgan Stanley Upgrade — Analyst Admits ‘We’ve Been On The Wrong Side’ Of The Enterprise Hardware Trade

Morgan Stanley also upgraded its broader U.S. IT Hardware industry view to In-Line from Cautious, citing evidence that the current hardware cycle is being driven by refreshes, pull-forwards and AI demand.


GLW Stock Sank 46% In July, Its Worst Monthly Drop In 24 Years — Truist Sees It As A Buying Opportunity

Corning’s shares ended in the red in 16 out of 22 trading sessions in July, with the stock plummeting in double-digits on three of those days.


RDDT Stock Set For Worst Day On Record — Reddit Advances Copyright Suit Against Perplexity In Crusade Against AI Data Scraping

Federal court clears Reddit to advance anti-circumvention claims against Perplexity AI and SerpApi, even as the platform navigates Google search traffic fluctuations following robust Q2 2026 earnings.


RDDT Stock Is In The Limelight Today After Massive Pre-Market Fall — GOOGL Friction Raises AI Licensing Risks, Says Wells Fargo

The selloff in Reddit shares came as investors looked past the earnings beat and focused on slowing U.S. user growth and management's commentary on its relationship with Google.


Vanguard Index Funds - Vanguard Morningstar Mid-Cap ETF

Bearish Sentiment

<ul class="summary-bullets"><li>CEO Yvonne Greenstreet noted the company is “not yet satisfied with the underlying demand growth” despite expanded sales force efforts.</li><li>CFO Jeff Poulton also flagged potential fourth-quarter ordering volatility as hospitals await a final Centers for Medicare &amp; Medicaid Services (CMS) rule on drug reimbursements.&nbsp;</li><li>Alnylam also said that its mid-stage data for ALN-6400 in hereditary hemorrhagic telangiectasia and early-stage data for ALN-2232 in obesity are now expected in February.</li></ul>Shares of Alnylam Pharmaceuticals (ALNY) fell roughly 26% on Thursday after the company signaled slower-than-expected demand growth for its flagship AMVUTTRA therapy, pushed back certain trial results, and highlighted near-term pressures from Medicare Advantage restrictions and proposed drug reimbursement changes.The stock hit a fresh 52-week low of $172.31 during the session and is on track for its worst day since late July, if the losses hold.<h2 class="st-heading-2">ALNY Flags Concerns</h2>Third-quarter net product revenues rose 52% to about $1.3 billion, driven by total transthyretin (TTR) &nbsp;franchise sales of $1.15 billion. Yet management said it now expects full-year TTR product sales to land at the low end of its $4.2 billion to $4.5 billion range.CEO Yvonne Greenstreet noted the company is “not yet satisfied with the underlying demand growth” despite expanded sales force efforts. Chief Commercialization Officer Tolga Tanguler added that increased physician engagement “has not yet translated into increased demand growth,” citing the time needed to shift entrenched prescribing habits among newer community physicians.On access, Tanguler highlighted a more restrictive first-line AMVUTTRA policy implemented by UnitedHealth in its Medicare Advantage business effective October 1. While existing patients are unaffected and an exception process exists, the change “could create some delays for new patients,” he said.CFO Jeff Poulton also flagged potential fourth-quarter ordering volatility as hospitals await a final Centers for Medicare &amp; Medicaid Services (CMS) rule on drug reimbursements, which, if finalized as proposed, would substantially cut Medicare payments for drugs acquired through the program, such as Alnylam’s Amvuttra, starting in 2027. The company said it will not issue 2027 product revenue guidance at the January JPMorgan conference and will wait until its fourth-quarter results in mid-February.Alnylam also said that its mid-stage data for ALN-6400 in hereditary hemorrhagic telangiectasia and early-stage data for ALN-2232 in obesity are now expected in February with fourth-quarter results, a modest delay from prior guidance of the second half of 2026.<h2 class="st-heading-2">Wall Street Weighs In On ALNY</h2>H.C. Wainwright analyst Patrick Trucchio attributed the stock’s selloff to discussion of Medicare Advantage step-therapy restrictions and potential disruption from changes to drug reimbursement rules. However, the firm views the selloff as an overreaction and reiterated a 'Buy' rating with a $455 price target. It sees the main risk as slower new starts rather than switching of existing patients, and added that it would not equate provider payment changes to an equivalent cut in Alnylam’s realized selling price.Stifel downgraded the stock to 'Hold' from 'Buy' and cut its target to $225 from $318, warning that near-term Amvuttra estimates are likely to come down “probably significantly” and that it is “hard to see a path for the stock with it not being a beat-and-raise story.” Jefferies noted the “slight push” to pipeline catalysts on bleeding and obesity programs and maintains a Hold rating.<h2 class="st-heading-2">How Did ALNY Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$ALNY" data-symbol-id="ALNY" href="https://stocktwits.com/symbol/ALNY" target="_blank">ALNY stock</a> rose from 'bearish' to 'neutral' territory over the past 24 hours while message volume jumped from 'normal' to 'high' levels.A Stocktwits user noted that the stock is now back to 2023 valuations.<stembedurl>https://stocktwits.com/Olena/message/667661748</stembedurl>ALNY stock has dropped 57% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cvna-stock-on-track-for-best-day-in-nearly-14-months-as-morgan-stanley-terms-it-top-pick-on-strong-q3-report/cZUQs7pR9R5">CVNA Stock On Track For Best Day In Nearly 14 Months As Morgan Stanley Terms It Top Pick On ‘Strong’ Q3 Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Alnylam Pharmaceuticals logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Alnylam management said it now expects full-year TTR product sales to land at the low end of its $4.2 billion to $4.5 billion range.

Alnylam Pharmaceuticals Inc

Vanguard Mid-Cap ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

VO Vanguard Mid-Cap ETF

Fundamentals

Latest VO News